National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over.


NCPE Assessment Process Complete
Rapid review commissioned 26/08/2019
Rapid review completed 04/11/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that mepolizumab not be considered for reimbursement under the high technology drugs arrangement at the submitted price*


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act